Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c
Get Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.85), $0.05 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $20 million versus the consensus estimate of $19.44 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
- L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!